Brii Biosciences Limited (2137.HK)
| Previous close | 1.370 |
| Open | 1.370 |
| Bid | 1.380 x N/A |
| Ask | 1.400 x N/A |
| Day's range | 1.320 - 1.430 |
| 52-week range | 0.850 - 4.240 |
| Volume | |
| Avg. volume | 4,297,166 |
| Market cap | 1.007B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.260 |
| Earnings date | 25 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.78 |
PR NewswireBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today provided a corporate update and reported its financial results for the year ended December 31, 2023.
PR NewswireBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), ensuring expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio's HBV functional cure portfolio.
- PR Newswire
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024. Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.
